Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 10/20 | 0.36 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.36 |
| ▸ | AXL | P30530 | 4/20 | 0.35 |
| ▸ | MERTK | Q12866 | 4/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.33 |
| ▸ | PRKCB | P05771 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17187996 | 1.00 | SSTR4 (0.36) | SSTR4SSTR1AXLMERTKBACE1 | |
| SCHEMBL22230101 | 0.81 | SMN1; SMN2 (0.31) | SSTR4 | |
| SCHEMBL25203468 | 0.79 | SSTR4 (0.34) | SSTR4SSTR1BACE1MAPK1 | |
| SCHEMBL18581645 | 0.79 | BACE1 (0.30) | BACE1 | |
| SCHEMBL18582039 | 0.79 | PRKCG (0.32) | PRKCEPRKCB | |
| SCHEMBL18581971 | 0.78 | CYP3A4 (0.31) | — | |
| SCHEMBL4354026 | 0.77 | ACACB (0.34) | — | |
| SCHEMBL20294713 | 0.77 | BACE1 (0.30) | BACE1 | |
| SCHEMBL3877927 | 0.76 | PPM1D (0.32) | — | |
| SCHEMBL3877935 | 0.76 | PPM1D (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969724-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170129880-A1 | FACTOR IXa INHIBITORS | MERCK SHARP & DOHME LLC | 2017-05-11 | — | — | US | disclosed |
| EP-3131897-A1 | FACTOR IXA INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-02-22 | — | — | EP | disclosed |
| WO-2015160636-A1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129880-A1 | FACTOR IXa INHIBITORS | F9, F12, TFPI | SSTR4 3845/4885SSTR1 3297/4885AXL 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.